Traditional Chinese medicine composition for treating phlegm-turbidity blocking type STEMI (St-elevation myocardial infarction) direct PCI (percutaneous coronary interention) postoperative myocardial perfusion deficiency

Abstract

The invention belongs to the technical field of medicine, and particularly relates to a traditional Chinese medicine composition for treating phlegm-turbidity blocking type STEMI (St-elevation myocardial infarction) direct PCI (percutaneous coronary interention) postoperative myocardial perfusion deficiency. The traditional Chinese medicine composition is prepared from the following ingredients in parts by weight: 2 to 4 parts of semen brassicae, 4 to 8 parts of acorus gramineus soland, 4 to 8 parts of Chinese alyxia herb, 4 to 8 parts of Bagusheng, 4 to 8 parts of dysosma versipellis, 4 to 8 parts of paeonia lactiflora, 4 to 8 parts of buddleja asiatica, 4 to 8 parts of plumbago indica and 4 to 8 parts of liquorice. All medicine is used and matched together for achieving the effects of eliminating phlegm for resuscitation, activating blood and dredging collaterals. The myocardial perfusion of a patient with STEMI direct PCI postoperative myocardial perfusion deficiency can be obviously improved.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a traditional Chinese medicine composition for treating poor myocardial perfusion after direct PCI of ST-segment elevation myocardial infarction with phlegm turbidity obstruction. Background technique [0002] Direct percutaneous coronary intervention (Percutaneous coronary intervention PCI) is the main treatment for acute ST-segment elevation myocardial infarction (St-elevationmyocardialinfarctionSTEMI). However, it has been clinically found that about 30% to 40% of patients with infarct-related arteries do not improve myocardial tissue microcirculation perfusion, that is, myocardial perfusion is poor. Studies have found that myocardial perfusion is the main cause of cardiovascular events and mortality. Therefore, how to adopt which treatment method can improve myocardial perfusion after STEMI primary PCI has important clinical significance. [0003] Western medic...

AI Technical Summary

Problems solved by technology

[0004] The technical problem to be solved by the present invention is to avoid the shortcomings of the above-mentioned prior art, and to provide a traditional Chinese medicine composition for the treatment of phlegm turbid obstruction type ST-segment elevation myocardial infarction and poor myocardial perfusion after direct PCI